Lantheus to Present New Data at the ASNC Annual Scientific Session on the Novel PET Cardiac Imaging Agent Flurpiridaz F 18 in Patients with Suspected Heart Disease Undergoing Exercise Stress Testing

News Findings show superiority of Flurpiridaz F 18 PET MPI compared to SPECT MPI for the assessment of coronary artery disease during exercise stress testing. Contributed Author:  Lantheus Holdings, Inc. Topics:  Cardiovascular